1
|
Interleukin-10 Conjugation to Carboxylated PVP-Coated Silver Nanoparticles for Improved Stability and Therapeutic Efficacy. NANOMATERIALS 2017; 7:nano7070165. [PMID: 28671603 PMCID: PMC5535231 DOI: 10.3390/nano7070165] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 06/08/2017] [Accepted: 06/29/2017] [Indexed: 12/13/2022]
Abstract
Interleukin-10 (IL-10) is a key anti-inflammatory and immunosuppressive cytokine and therefore represents a potential therapeutic agent especially in inflammatory diseases. However, despite its proven therapeutic efficacy, its short half-life and proteolytic degradation in vivo combined with its low storage stability have limited its therapeutic use. Strategies have been developed to overcome most of these shortcomings, including in particular bioconjugation with stabilizing agents such as polyethylene glycol (PEG) and poly (vinylpyrolidone) (PVP), but so far these have had limited success. In this paper, we present an alternative method consisting of bioconjugating IL-10 to PVP-coated silver nanoparticles (Ag-PVPs) in order to achieve its storage stability by preventing denaturation and to improve its anti-inflammatory efficacy. Silver nanoparticles capped with a carboxylated PVP were produced and further covalently conjugated with IL-10 protein by carbodiimide crosslinker chemistry. The IL-10 conjugated Ag-PVPs exhibited increased stability and anti-inflammatory effectiveness in vitro. This study therefore provides a novel approach to bioconjugating PVP-coated silver nanoparticles with therapeutic proteins, which could be useful in drug delivery and anti-inflammatory therapies.
Collapse
|
2
|
Liu Q, Wu H, Zhang L, Zhou Y, Zhang W, Pan X, Zhang Z, Zhu X. RAFT polymerization of N-vinylpyrrolidone mediated by cyanoprop-2-yl-1-dithionaphthalate in the presence of a fluoroalcohol: the possibility of altering monomer properties by hydrogen bonding? Polym Chem 2016. [DOI: 10.1039/c5py02047f] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
This work illustrated the possibility of altering the monomer properties by using the hydrogen bonding interaction.
Collapse
Affiliation(s)
- Qingqing Liu
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| | - Huaqiao Wu
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| | - Liuqiao Zhang
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| | - Yu Zhou
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| | - Wei Zhang
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| | - Xiangqiang Pan
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| | - Zhengbiao Zhang
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| | - Xiulin Zhu
- Suzhou key Laboratory of Macromolecular Design and Precision Synthesis
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Department of Polymer Science and Engineering
- College of Chemistry
- Chemical Engineering and Materials Science
| |
Collapse
|
3
|
Wang Z, Ma G, Zhang J, Lin W, Ji F, Bernards MT, Chen S. Development of zwitterionic polymer-based doxorubicin conjugates: tuning the surface charge to prolong the circulation and reduce toxicity. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2014; 30:3764-3774. [PMID: 24617705 DOI: 10.1021/la5000765] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Polymer-drug conjugates are commonly used as nano drug vehicles (NDVs) to delivery anticancer drugs. Zwitterionic polymers are ideal candidates to conjugate drugs because they show higher resistance to nonspecific protein adsorption in complex media than that of nonionic water-soluble polymers, such as poly(ethylene glycol). However, the charge balance characteristics of zwitterionic polymers used as NDVs will be broken from the inclusion of additional charged groups brought by conjugated drugs or functional groups, leading to the loss of resistance to protein adsorption. Consequently, the nonspecific protein adsorption on drug carriers will cause fast clearance from the blood system, an immune response, or even severe systemic toxicity. To overcome this drawback, a model zwitterionic polymer, poly(carboxybetaine methacrylate) (pCBMA), was modified by the introduction of a negatively charged component, to neutralize the positive charge provided by the model drug, doxorubicin (DOX). A DOX-conjugated NDV which possesses excellent resistance to nonspecific protein adsorption was achieved by the formation of a strongly hydrated pCBMA shell with a slightly negative surface charge. This kind of DOX-conjugated NDV exhibited reduced cytotoxicity and prolonged circulation time, and it accelerated DOX release under mild acid conditions. In tumor-bearing mouse studies a 55% tumor-inhibition rate was achieved without causing any body weight loss. These results indicate the importance of charge tuning in zwitterionic polymer-based NDVs.
Collapse
Affiliation(s)
- Zhen Wang
- State Key Laboratory of Chemical Engineering, Department of Chemical and Biological Engineering, Zhejiang University , Hangzhou, Zhejiang 310027, P. R. China
| | | | | | | | | | | | | |
Collapse
|
4
|
Kryger MBL, Smith AAA, Wohl BM, Zelikin AN. Macromolecular prodrugs for controlled delivery of ribavirin. Macromol Biosci 2013; 14:173-85. [PMID: 24105953 DOI: 10.1002/mabi.201300244] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2013] [Revised: 08/05/2013] [Indexed: 12/21/2022]
Abstract
Ribavirin (RBV)-containing polymers are synthesized based on poly(N-vinylpyrrolidone) and poly(acrylic acid), two polymers with extensive characterization in biomedicine. The copolymers are shown to exhibit a minor to negligible degree of association with erythrocytes, thus effectively eliminating the origin of the main side effects of RBV. The therapeutic benefit of macromolecular RBV prodrugs is illustrated by matched efficacy in suppressing production of nitric oxide by stimulated cultured macrophages as compared to pristine RBV with no associated cytotoxicity, which is in stark contrast to an RBV-based treatment which results in a significant decrease in cell viability. These results contribute to the development of antiviral polymer therapeutics and delivery of RBV in particular.
Collapse
Affiliation(s)
- Mille B L Kryger
- Interdisciplinary Nanoscience Centre (iNANO), Gustav WiedsVej 14, DK-8000, Aarhus C, Denmark
| | | | | | | |
Collapse
|
5
|
Trellenkamp T, Ritter H. Poly(N-vinylpyrrolidone) Bearing Covalently Attached Cyclodextrin via Click-Chemistry: Synthesis, Characterization, and Complexation Behavior with Phenolphthalein. Macromolecules 2010. [DOI: 10.1021/ma100812q] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Taina Trellenkamp
- Heinrich-Heine-University Düsseldorf, Institute of Organic Chemistry und Macromolecular Chemistry Universitätsstrasse 1, 40225 Düsseldorf, Germany
| | - Helmut Ritter
- Heinrich-Heine-University Düsseldorf, Institute of Organic Chemistry und Macromolecular Chemistry Universitätsstrasse 1, 40225 Düsseldorf, Germany
| |
Collapse
|
6
|
Trellenkamp T, Ritter H. 3-EthylatedN-Vinyl-2-pyrrolidone with LCST Properties in Water. Macromol Rapid Commun 2009; 30:1736-40. [DOI: 10.1002/marc.200900250] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2009] [Revised: 06/02/2009] [Accepted: 06/03/2009] [Indexed: 11/09/2022]
|
7
|
ETO Y, YOSHIOKA Y, ASAVATANABODEE R, MIZUGUCHI H, MUKAI Y, OKADA N, NAKAGAWA S. Development of PEGylated Adenovirus Vector for Cancer Gene Therapy. YAKUGAKU ZASSHI 2008; 128:1733-42. [DOI: 10.1248/yakushi.128.1733] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Yusuke ETO
- Guraduate School of Pharmaceutical Siences, Osaka University
| | - Yasuo YOSHIOKA
- Guraduate School of Pharmaceutical Siences, Osaka University
- MEI Center, Osaka University
| | | | | | - Yohei MUKAI
- Guraduate School of Pharmaceutical Siences, Osaka University
| | - Naoki OKADA
- Guraduate School of Pharmaceutical Siences, Osaka University
| | - Shinsaku NAKAGAWA
- Guraduate School of Pharmaceutical Siences, Osaka University
- MEI Center, Osaka University
| |
Collapse
|
8
|
Baldoli C, Oldani C, Maiorana S, Ferruti P, Ranucci E, Bencini M, Contini A. Functionalization and molecular dynamics study of carboxy-terminated poly(1-vinylpyrrolidin-2-one): A potential soluble carrier of biomolecules. ACTA ACUST UNITED AC 2008. [DOI: 10.1002/pola.22510] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
9
|
Pound G, McKenzie JM, Lange RFM, Klumperman B. Polymer–protein conjugates from ω-aldehyde endfunctional poly(N-vinylpyrrolidone) synthesised via xanthate-mediated living radical polymerisation. Chem Commun (Camb) 2008:3193-5. [DOI: 10.1039/b803952f] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
10
|
Bencini M, Ranucci E, Ferruti P, Manfredi A. New Stimuli Responsive Poly(1-vinylpyrrolidin-2-one) Bearing Pendant Activated Disulfide Groups. Macromol Rapid Commun 2006. [DOI: 10.1002/marc.200600194] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
11
|
Engström JUA, Lindgren LJ, Helgee B. Synthesis of Novel Monomers and Copolymers from 1-Vinylpyrrolidin-2-one: Attractive Materials for Drug Delivery Systems? MACROMOL CHEM PHYS 2006. [DOI: 10.1002/macp.200500479] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
12
|
Abstract
Polymers occupy a major portion of materials used for controlled release formulations and drug-targeting systems because this class of materials presents seemingly endless diversity in topology and chemistry. This is a crucial advantage over other classes of materials to meet the ever-increasing requirements of new designs of drug delivery formulations. The polymer architecture (topology) describes the shape of a single polymer molecule. Every natural, seminatural, and synthetic polymer falls into one of categorized architectures: linear, graft, branched, cross-linked, block, star-shaped, and dendron/dendrimer topology. Although this topic spans a truly broad area in polymer science, this review introduces polymer architectures along with brief synthetic approaches for pharmaceutical scientists who are not familiar with polymer science, summarizes the characteristic properties of each architecture useful for drug delivery applications, and covers recent advances in drug delivery relevant to polymer architecture.
Collapse
Affiliation(s)
- Li Yan Qiu
- Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 421 Wakara Way, Suite 315, Salt Lake City, Utah 84108, USA
| | | |
Collapse
|
13
|
Optimization of protein therapies by polymer-conjugation as an effective DDS. Molecules 2005; 10:162-80. [PMID: 18007284 PMCID: PMC6147742 DOI: 10.3390/10010162] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2004] [Revised: 09/27/2004] [Accepted: 12/12/2004] [Indexed: 11/17/2022] Open
Abstract
Due to recent advances in disease proteomics, many disease-related proteins have been found. It is expected that there will be therapeutically useful proteins among them. However, it is clinically difficult to use most proteins as effective and safe drugs because of their very low stability and pleiotropic actions in vivo. To promote disease proteomic based drug development for protein therapies, we have attempted to develop an optimal polymer-conjugation system for improving the therapeutic potency of proteins. In this review, we introduce this innovative protein-drug system.
Collapse
|
14
|
D'Souza AJM, Schowen RL, Topp EM. Polyvinylpyrrolidone-drug conjugate: synthesis and release mechanism. J Control Release 2004; 94:91-100. [PMID: 14684274 DOI: 10.1016/j.jconrel.2003.09.014] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Covalent conjugates of polyvinylpyrrolidone (PVP) with para-nitroaniline (PNA) were synthesized as a model PVP-drug conjugate, and PNA release was evaluated in vitro. Pyrrolidone ring opening with subsequent t-BOC protection of the pyrrolidone nitrogen and reaction with PNA in methylene chloride (CH2Cl2) produced a PVP-PNA conjugate with 3% of the pyrrolidone groups modified. Rates of PNA release from N-deprotected conjugates were twofold greater than those that were N-protected, indicating participation of the pyrrolidone N in release. Additional studies with monomeric analogs supported intramolecular base catalysis rather than lactam formation as the mechanism of this involvement. The approach serves as a prototype for the conjugation of other drugs with primary and secondary amine functional groups with PVP, including peptides and proteins.
Collapse
Affiliation(s)
- Ajit Joseph M D'Souza
- Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave., Lawrence, KS 66047, USA
| | | | | |
Collapse
|
15
|
Abstract
With the success of the human genome project, the focus of life science research has shifted to the functional and structural analyses of proteins, such as proteomics and structural genomics. These analyses of proteins including newly identified proteins are expected to contribute to the identification of therapeutically applicable proteins for various diseases. Thus, pharmaco-proteomic-based drug discovery and development for protein therapies, including gene therapy, cell therapy, and vaccine therapy, is attracting current attention. However, there is clinical difficulty in using almost all bioactive proteins, because of their very low stability and pleiotropic actions in vivo. To promote pharmaco-proteomic-based drug discovery and development, we have attempted to develop drug delivery systems (DDSs), such as the protein-drug innovation system and the optimal cell therapeutic system. In this review, we introduce our original DDSs.
Collapse
Affiliation(s)
- Tadanori Mayumi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan.
| |
Collapse
|
16
|
Kamada H, Tsutsumi Y, Yoshioka Y, Yamamoto Y, Kodaira H, Tsunoda SI, Okamoto T, Mukai Y, Shibata H, Nakagawa S, Mayumi T. Design of a pH-Sensitive Polymeric Carrier for Drug Release and Its Application in Cancer Therapy. Clin Cancer Res 2004; 10:2545-50. [PMID: 15073135 DOI: 10.1158/1078-0432.ccr-03-0544] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE In this study, to optimize the polymeric drug delivery system for cancer chemotherapy, we developed a new pH-sensitive polymeric carrier, poly(vinylpyrrolidone-co-dimethylmaleic anhydride) [PVD], that could gradually release native form of drugs with full activity, from the conjugates in response to changes in pH. We examined the usefulness of PVD as a polymeric drug carrier. EXPERIMENTAL DESIGN PVD was radically synthesized with vinylpyrrolidone and 2,3-dimethylmaleic anhydride, which is known to be a pH-reversible amino-protecting reagent. Conjugates between PVD and other drugs, such as Adriamycin (ADR), were prepared under the slightly basic conditions (pH 8.5). The drug-release pattern and the antitumor activity of PVD were examined. RESULTS At pH 8.5, the release of the drugs from the conjugate was not observed. In contrast, PVD could release fully active drugs in the native form in response to the change in pH near neutrality, and gradually released drugs at neutral pH (7.0) and slightly acidic pH (6.0). The drug-release pattern in serum was almost similar to that observed during these physiological conditions. The PVD-conjugated ADR showed superior antitumor activity against sarcoma-180 solid tumor in mice, and it had less toxic side effects than free ADR. This enhancement in the antitumor therapeutic window may be due to not only the improvement of plasma half-lives and tumor accumulation of ADR, but also its controlled and sustained release from the conjugates in vivo. CONCLUSIONS These results indicate that PVD is an effective polymeric carrier for optimizing cancer therapy.
Collapse
Affiliation(s)
- Haruhiko Kamada
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Yoshioka Y, Tsutsumi Y, Mukai Y, Shibata H, Okamoto T, Kaneda Y, Tsunoda SI, Kamada H, Koizumi K, Yamamoto Y, Mu Y, Kodaira H, Sato-Kamada K, Nakagawa S, Mayumi T. Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleen. ACTA ACUST UNITED AC 2004; 70:219-23. [PMID: 15227666 DOI: 10.1002/jbm.a.30059] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
To optimize polymer-conjugated drugs as a polymeric drug delivery system, it is essential to design polymeric carriers with tissue-specific targeting capacity. Previously, we showed that polyvinylpyrrolidone (PVP) was the most suitable polymeric carrier for prolonging the blood-residency of drugs, and was one of the best parent polymers to design the polymeric carriers with targeting capacity. In this study, we synthesized some hydrophobic PVP derivatives, poly(vinylpyrrolidone-co-styrene) [poly(VP-co-S)] and poly(vinylpyrrolidone-co-vinyl laurate) [poly(VP-co-VL)], and assessed their biopharmaceutical properties after intravenous administration in mice. The elimination of hydrophobic PVP derivatives from blood was the same as PVP, and the plasma half-lives of poly(VP-co-S) were almost similar to that of poly(VP-co-VL). Poly(VP-co-VL) efficiently accumulated in the spleen, whereas poly(VP-co-S) effectively accumulated in the liver. The level of poly(VP-co-VL) in the spleen was about 20 times higher than PVP and poly(VP-co-S). These hydrophobic PVP derivatives did not show any cytotoxicity against endothelial cells in vitro. Thus, poly(VP-co-VL) may be a useful polymeric carrier for drug delivery to the spleen. This study will provide useful information to design optimal polymeric carriers with targeting capacity to the spleen and liver.
Collapse
Affiliation(s)
- Yasuo Yoshioka
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Baritaki S, Tzanakakis GN, Alifragis J, Zafiropoulos A, Tashmukhamedov RI, Tsatsakis A, Shtilman MI, Rizos AK, Krambovitis E. Light scattering and in vitro biocompatibility studies of poly (vinyl pyrrolidone) derivatives with amino-acid-dependent groups. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH 2003; 63:830-7. [PMID: 12418031 DOI: 10.1002/jbm.10409] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Two poly (vinyl pyrrolidone) (PVP) families with amino-acid residues (glycine, beta-alanine, gamma-aminobutiric acid and epsilon-aminocaproic acid) on the base of the co-polymer N-vinyl pyrrolidone and allyl-glycidyl ether (VP-AGE) and on the base of epoxidized PVP (EPVP) were synthesized. Static and dynamic light scattering measurements of these PVP derivatives in water showed that their structure/ behavior were similar to that of PVP. The bioreactivity was also similar to that of PVP. Further investigation of the immunoreactive properties of the derivatives in in vitro proliferation assays with fresh normal human peripheral blood lymphocytes and monocytes led to the determination of a costimulatory profile for each derivative in terms of polyclonal stimulation, specific antigen presentation, and immunoglobulin secretion. This profile allows the selection of an appropriate derivative as a carrier that would suit the immunoreactivity needs of the immobilized ligand.
Collapse
Affiliation(s)
- Stavroula Baritaki
- Department of Applied Biochemistry & Immunology, Institute of Molecular Biology & Biotechnology, Vassilika Vouton, 71110 Heraklion, Crete, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nagata S, Mayumi T. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 2003; 21:546-52. [PMID: 12665803 DOI: 10.1038/nbt812] [Citation(s) in RCA: 170] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2002] [Accepted: 01/02/2003] [Indexed: 11/09/2022]
Abstract
Addition of polyethylene glycol to protein (PEGylation) to improve stability and other characteristics is mostly nonspecific and may occur at all lysine residues, some of which may be within or near an active site. Resultant PEGylated proteins are heterogeneous and can show markedly lower bioactivity. We attempted to develop a strategy for site-specific mono-PEGylation using tumor necrosis factor-alpha (TNF-alpha). We prepared phage libraries expressing TNF-alpha mutants in which all the lysine residues were replaced with other amino acids. A fully bioactive lysine-deficient mutant TNF-alpha (mTNF-alpha-Lys(-)) was isolated by panning against TNF-alpha-neutralizing antibody despite reports that some lysine residues were essential for its bioactivity. mTNF-alpha-Lys(-) was site-specifically mono-PEGylated at its N terminus. This mono-PEGylated mTNF-alpha-Lys(-), with superior molecular uniformity, showed higher bioactivity in vitro and greater antitumor therapeutic potency than randomly mono-PEGylated wild-type TNF-alpha. These results suggest the usefulness of the phage display system for creating functional mutant proteins and of our site-specific PEGylation approach.
Collapse
Affiliation(s)
- Yoko Yamamoto
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Kamada H, Tsutsumi Y, Sato-Kamada K, Yamamoto Y, Yoshioka Y, Okamoto T, Nakagawa S, Nagata S, Mayumi T. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat Biotechnol 2003; 21:399-404. [PMID: 12612587 DOI: 10.1038/nbt798] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2002] [Accepted: 12/23/2002] [Indexed: 11/08/2022]
Abstract
We have synthesized a polymeric drug carrier, polyvinylpyrrolidone-co-dimethyl maleic anhydride [poly(VP-co-DMMAn)], for use in renal drug delivery. About 80% of the 10-kDa poly(VP-co-DMMAn) selectively accumulated in the kidneys 24 h after intravenous administration to mice. Although this accumulated poly(VP-co-DMMAn) was gradually excreted in the urine, about 40% remained in the kidneys 96 h after treatment. Poly(VP-co-DMMAn) was taken up by the renal proximal tubular epithelial cells and no cytotoxicity was noted. Higher doses did not produce toxicity in the kidneys or other tissues. In contrast, polyvinylpyrrolidone of the same molecular weight did not show any tissue-specific distribution. Poly(VP-co-DMMAn)-modified superoxide dismutase accumulated in the kidneys after intravenous administration and accelerated recovery from acute renal failure in a mouse model. In contrast, polyvinylpyrrolidone-modified superoxide dismutase and native superoxide dismutase were not as effective. Thus, poly(VP-co-DMMAn) is a useful candidate as a targeting carrier for renal drug delivery systems.
Collapse
Affiliation(s)
- Haruhiko Kamada
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Degelmann A, Müller F, Sieber H, Jenzelewski V, Suckow M, Strasser AW, Gellissen G. Strain and process development for the production of human cytokines inHansenula polymorpha. FEMS Yeast Res 2002. [DOI: 10.1111/j.1567-1364.2002.tb00104.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|